Delivery Order SPE2DB24D1007-SPE2DB25FCCUN
- Not listed
- The Defense Logistics Agency awarded a $42,553.88 delivery order to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of Zepbound 7.5 mg/0.5 mL pens, a GLP-1 receptor agonist medication used for weight management and diabetes treatment. This competitively awarded, firm fixed-price delivery order is scheduled for completion by September 10, 2025, with performance taking place at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The contract carries no set-aside...
- The Defense Logistics Agency awarded a $1,525.20 delivery order to AmerisourceBergen Drug Corp for Zepbound 5 mg/0.5 ml pen (0.5 ml), a GLP-1 receptor agonist medication used for weight management. This firm fixed-price, competitively awarded delivery order was issued on September 3, 2025, with an ultimate completion date of September 4, 2025, and will be fulfilled from the contractor's facility in Conshohocken, Pennsylvania. The award carries no set-aside designation. This delivery order is...
- The Defense Logistics Agency awarded a $9,725.21 delivery order to AmerisourceBergen Drug Corp on August 6, 2025, for the supply of Zepbound 7.5 mg/0.5 mL pens, a GLP-1 receptor agonist medication used in diabetes and weight management treatment. This firm fixed-price, competitively awarded delivery order is set to be completed by August 7, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $1,906.47 for Zepbound 2.5 mg/0.5 ml pen (0.5 ml), a GLP-1 receptor agonist medication used for weight management. This firm fixed-price, competitively awarded delivery order is scheduled for completion by August 11, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The contract carries no set-aside designation. This delivery order is issued under AmerisourceBergen...
- The Defense Logistics Agency awarded a $11,086.64 delivery order to AmerisourceBergen Drug Corp for Zepbound 2.5 mg/0.5 mL pen injectors (0.5 mL), a GLP-1 receptor agonist medication used for weight management. This firm fixed price, non-set-aside contract was awarded on August 25, 2025, with an ultimate completion date of August 26, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 1, 2025, for the supply of Zepbound 12.5 mg/0.5 mL pens, a GLP-1 receptor agonist medication used for weight management. This competitively awarded, firm fixed-price delivery order carries a ceiling value of $3,050.40 and an ultimate completion date of August 4, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania....
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for pharmaceutical supplies on August 14, 2025, with a ceiling value of $1,143.87. This non-set-aside, competitively awarded contract calls for the delivery of Zepbound 15 mg/0.5 mL pen injections, a GLP-1 receptor agonist medication used in weight management and diabetes treatment. The order is structured as a firm fixed-price delivery order with an ultimate completion date of August 15, 2025, and will be...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $4,575.48 to AmerisourceBergen Drug Corp for the supply of Zepbound 2.5 mg/0.5 ml pen (0.5 ml), a GLP-1 receptor agonist medication used for weight management. The contract was awarded on September 17, 2025, with an ultimate completion date of September 18, 2025, and represents a competitively awarded, firm fixed-price transaction with no set-aside designation. The place of performance is AmerisourceBergen's corporate office...
- The Defense Logistics Agency awarded a $2,831.76 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Zepbound 15 mg/0.5 mL pen injections on August 8, 2025, with an ultimate completion date of August 11, 2025. This non-set-aside contract represents a small-value transaction for the supply of this GLP-1 receptor agonist medication used in weight management and metabolic health treatment. The delivery order is being performed at AmerisourceBergen's corporate office location in...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on May 12, 2025, for the supply of Zepbound 2.5 mg/0.5 mL pens (0.5 mL), a GLP-1 receptor agonist medication used for weight management. This firm fixed price delivery order, valued at $23,538.60, is set to be completed by May 13, 2025, with performance at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award is a competitive, non-set-aside delivery order and represents a child...
- SPE2DB24D1007Indefinite Delivery Contract
- SPE2DB24D1007-SPE2DB25FCCUNDelivery Order
The Defense Logistics Agency awarded a $2,089.68 delivery order to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of Zepbound 10 mg/0.5 mL pens, a GLP-1 receptor agonist indicated for weight management. This firm fixed-price delivery order, which will be completed by August 12, 2025, represents a direct purchase under an existing contract vehicle and carries no set-aside designation. The product will be delivered to the company's location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at approximately $1 billion through December 2026. As a major pharmaceutical distributor serving federal healthcare systems, AmerisourceBergen Drug Corp supplies a comprehensive range of medications and medical supplies to support military, veterans, and other government healthcare programs globally. The competitively awarded IDC enables flexible procurement of pharmaceutical products across multiple therapeutic categories, positioning the company as a critical vendor in the federal medical supply chain for the Department of Defense and other government agencies.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.1k | 8/11/25 |